دورية أكاديمية
Antihypertensive Potential of Pistacia lentiscus var. Chia : Molecular Insights and Therapeutic Implications.
العنوان: | Antihypertensive Potential of Pistacia lentiscus var. Chia : Molecular Insights and Therapeutic Implications. |
---|---|
المؤلفون: | Efentakis P; Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Zografou, Greece., Symeonidi L; Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Zografou, Greece., Gianniou DD; Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784 Athens, Greece., Mikropoulou EV; Division of Pharmacognosy and Natural Products Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, Greece., Giardoglou P; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University of Athens, 17671 Athens, Greece., Valakos D; Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece., Vatsellas G; Greek Genome Centre, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece., Tsota M; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University of Athens, 17671 Athens, Greece., Kostomitsopoulos N; Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece., Smyrnioudis I; Mastiha Research Center, Seleperos Kallimasia, 82150 Chios, Greece., Trougakos IP; Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784 Athens, Greece., Halabalaki M; Division of Pharmacognosy and Natural Products Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, 15771 Athens, Greece., Dedoussis GV; Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University of Athens, 17671 Athens, Greece., Andreadou I; Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Zografou, Greece. |
المصدر: | Nutrients [Nutrients] 2024 Jul 05; Vol. 16 (13). Date of Electronic Publication: 2024 Jul 05. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI Publishing |
مواضيع طبية MeSH: | Pistacia*/chemistry , Hypertension*/drug therapy , Antihypertensive Agents*/pharmacology , Blood Pressure*/drug effects, Animals ; Male ; Rats ; Kidney/drug effects ; Kidney/metabolism ; Mastic Resin ; Disease Models, Animal ; Angiotensin II ; Rats, Sprague-Dawley ; Desoxycorticosterone Acetate ; Oxidative Stress/drug effects ; Endothelium, Vascular/drug effects ; Plant Extracts/pharmacology |
مستخلص: | Background: Hypertension poses a significant global health burden and is associated with cardiovascular morbidity. Chios mastic gum (CMG), derived from Pistacia lentiscus var. Chia , shows potential as a phytotherapeutic agent, due to its multifaceted beneficial effects. However, its anti-hypertensive effects and vascular, circulatory, and renal-related dysfunction, have not been thoroughly investigated. Herein, we aimed to explore the antihypertensive potential of CMG, focusing on vascular and renal endothelium, in vivo. Methods: Two models of hypertension in male rats, induced by Angiotensin II and Deoxycorticosterone acetate (DOCA)-high-salt administration, were utilized. CMG was administered at 220 mg/kg daily for four weeks after hypertension onset and blood pressure was measured non-invasively. Whole blood RNA sequencing, metabolomics, real-time PCR, and Western blot analyses of kidney and aorta tissues were additionally performed. Results: CMG significantly lowered systolic, diastolic, and mean blood pressure in both models. RNA sequencing revealed that CMG modulated immunity in the Angiotensin II model and metabolism in the DOCA-HS model. CMG downregulated genes related to oxidative stress and endothelial dysfunction and upregulated endothelial markers such as Vegfa. Metabolomic analysis indicated improved endothelial homeostasis via lysophosphatidylinositol upregulation. Conclusions: CMG emerges as a potent natural antihypertensive therapy, demonstrating beneficial effects on blood pressure and renal endothelial function. |
References: | Hypertension. 2002 Aug;40(2):190-4. (PMID: 12154112) Circ Res. 2004 Jul 23;95(2):210-6. (PMID: 15192025) J Hum Hypertens. 2023 Aug;37(8):619-625. (PMID: 36335169) Am J Hypertens. 2010 Nov;23(11):1159-69. (PMID: 20864945) J Am Soc Nephrol. 2002 Dec;13(12):2860-8. (PMID: 12444204) Eur Heart J. 2023 Jun 20;44(23):2066-2077. (PMID: 36342266) Pharmacol Res. 2023 Aug;194:106821. (PMID: 37329633) Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700) Anal Chem. 2018 Mar 6;90(5):3156-3164. (PMID: 29381867) Biochem Pharmacol. 2022 Dec;206:115321. (PMID: 36306821) J Ethnopharmacol. 2024 Feb 10;320:117436. (PMID: 37979813) Blood. 2019 Feb 14;133(7):710-723. (PMID: 30482794) Am J Physiol Renal Physiol. 2004 May;286(5):F848-57. (PMID: 15075180) Curr Atheroscler Rep. 2023 Sep;25(9):605-612. (PMID: 37594602) Am J Pathol. 2007 Mar;170(3):1108-20. (PMID: 17322393) Hemasphere. 2022 Oct 18;6(11):e791. (PMID: 36285072) Br J Pharmacol. 2022 Mar;179(5):918-937. (PMID: 34363610) Nature. 1999 Jun 10;399(6736):601-5. (PMID: 10376603) Hypertension. 2003 Nov;42(5):1004-13. (PMID: 14557279) Acta Physiol (Oxf). 2021 Jan;231(1):e13487. (PMID: 32359222) Hypertens Res. 2011 Jun;34(6):674-83. (PMID: 21412242) Pulm Pharmacol Ther. 2014 Jun;28(1):17-24. (PMID: 24269521) Hypertension. 2004 Nov;44(5):595-601. (PMID: 15452024) Genome Biol. 2014;15(12):550. (PMID: 25516281) J Biol Chem. 2002 Mar 22;277(12):9655-60. (PMID: 11751890) Theranostics. 2022 Jul 11;12(12):5434-5450. (PMID: 35910788) Br J Pharmacol. 2009 Jul;157(6):907-21. (PMID: 19508398) Genes Dis. 2020 Aug 31;9(3):753-765. (PMID: 35782967) Foods. 2022 Jan 20;11(3):. (PMID: 35159423) Ann Transl Med. 2018 Jun;6(12):256. (PMID: 30069458) Phytomedicine. 2022 Sep;104:154329. (PMID: 35843187) Curr Hypertens Rep. 2018 Aug 17;20(10):89. (PMID: 30120623) Hypertension. 2018 Oct;72(4):796-805. (PMID: 30354723) Hypertension. 2023 May;80(5):901-911. (PMID: 36748474) Cardiooncology. 2020 Aug 27;6:15. (PMID: 32864163) Hypertension. 2005 Sep;46(3):492-9. (PMID: 16116047) Hypertension. 2019 Dec;74(6):1436-1447. (PMID: 31679426) Hypertension. 2008 Apr;51(4):811-6. (PMID: 18332286) Nucleic Acids Res. 2022 Jan 7;50(D1):D622-D631. (PMID: 34986597) Hypertension. 2018 Apr;71(4):638-647. (PMID: 29483228) Br J Pharmacol. 2010 Aug;160(7):1577-9. (PMID: 20649561) Hypertension. 2021 May 5;77(5):1591-1599. (PMID: 33775123) Front Physiol. 2017 Nov 15;8:928. (PMID: 29187825) Phytomedicine. 2016 Oct 15;23(11):1220-6. (PMID: 27316396) J Ethnopharmacol. 2020 May 23;254:112485. (PMID: 32092498) J Am Heart Assoc. 2016 Oct 26;5(11):. (PMID: 27912206) Eur Heart J. 2022 Feb 10;43(6):488-500. (PMID: 34132336) Physiol Res. 2013;62(4):351-9. (PMID: 23590610) Curr Hypertens Rep. 2017 Apr;19(4):32. (PMID: 28353076) Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7. (PMID: 27141961) Nat Methods. 2015 Apr;12(4):357-60. (PMID: 25751142) J Heart Lung Transplant. 2016 Apr;35(4):481-90. (PMID: 26774383) Biomed Pharmacother. 2018 Sep;105:899-906. (PMID: 30021383) J Mass Spectrom. 2010 Jul;45(7):703-14. (PMID: 20623627) Circulation. 2012 Mar 27;125(12):1520-32. (PMID: 22371328) JACC Basic Transl Sci. 2023 Apr 26;8(7):884-904. (PMID: 37547069) Curr Mol Pharmacol. 2021;14(6):935-942. (PMID: 33390142) Br J Pharmacol. 2019 Jun;176(12):1966-1977. (PMID: 29885051) Nat Med. 2003 Aug;9(8):1026-32. (PMID: 12872165) J Clin Hypertens (Greenwich). 2011 Apr;13(4):244-51. (PMID: 21466619) Phytomedicine. 2018 Nov 15;50:166-177. (PMID: 30466975) Metabolites. 2016 Jan 15;6(1):. (PMID: 26784247) Front Oncol. 2021 Mar 24;11:642547. (PMID: 33842351) BMC Bioinformatics. 2010 Jul 23;11:395. (PMID: 20650010) Basic Res Cardiol. 2021 Jul 17;116(1):44. (PMID: 34275052) Curr Cardiol Rev. 2010 Nov;6(4):291-7. (PMID: 22043205) Vascul Pharmacol. 2022 Oct;146:107095. (PMID: 35944842) |
معلومات مُعتمدة: | T2ΕΔΚ-00547 EPAnEK 2014-2020 |
فهرسة مساهمة: | Keywords: chios mastic gum; hypertension; phytotherapeutic; renal endothelium |
المشرفين على المادة: | 0 (Antihypertensive Agents) 0 (Mastic Resin) 11128-99-7 (Angiotensin II) 6E0A168OB8 (Desoxycorticosterone Acetate) 0 (Plant Extracts) |
تواريخ الأحداث: | Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240715 |
رمز التحديث: | 20240715 |
مُعرف محوري في PubMed: | PMC11243328 |
DOI: | 10.3390/nu16132152 |
PMID: | 38999899 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2072-6643 |
---|---|
DOI: | 10.3390/nu16132152 |